Venous Thromboembolism

/Tag:Venous Thromboembolism

Abstract Number: Oral

DEVELOPMENT AND VALIDATION OF A RISK ASSESSMENT MODEL FOR VTE IN HOSPITALIZED MEDICAL PATIENTS

Background: Venous thromboembolism (VTE) is the leading cause of preventable hospital death. National guidelinesrecommend VTE prophylaxis for all medical patients not at low risk. Several VTE risk prediction models have been developed, but no US [...]

By | 2019-03-12T15:50:05-04:00 March 11th, 2019|Hospital Medicine 2019, Oral Presentations, Outcomes Research, Research|Comments Off on DEVELOPMENT AND VALIDATION OF A RISK ASSESSMENT MODEL FOR VTE IN HOSPITALIZED MEDICAL PATIENTS

Abstract Number: 841

MANY FACES OF MAY THURNER SYNDROME: CHANGING YOUR PERSPECTIVE

Case Presentation: 73-year-old male with past medical history of seizure disorder, non insulin dependent diabetes mellitus, hyperlipidemia presents for evaluation of pain and swelling of right lower extremity, found to have deep venous thrombosis involving [...]

By | 2019-03-11T14:37:32-04:00 March 11th, 2019|Adult, Clinical Vignettes, Hospital Medicine 2019|Comments Off on MANY FACES OF MAY THURNER SYNDROME: CHANGING YOUR PERSPECTIVE

Abstract Number: 612

PULMONARY EMBOLUS AND LEFT LOWER EXTREMITY DEEP VEIN THROMBOSIS IN A YOUNG FEMALE

Case Presentation: A 17 year old female was diagnosed with a pulmonary embolus 3 months ago. A partially occlusive thrombus was also noted in her left common iliac vein. She was diagnosed with May-Thurner syndrome [...]

By | 2019-03-11T14:31:04-04:00 March 11th, 2019|Adult, Clinical Vignettes, Hospital Medicine 2019|Comments Off on PULMONARY EMBOLUS AND LEFT LOWER EXTREMITY DEEP VEIN THROMBOSIS IN A YOUNG FEMALE

Abstract Number: 329

COMBINING LEAN SIX-SIGMA QUALITY IMPROVEMENT METHODS WITH SAFETY BARRIER ANALYSIS TO DEVELOP INTERVENTIONS THAT REDUCE HOSPITAL-ACQUIRED VENOUS THROMBOEMBOLISM (HA-VTE)

Background: The U.S. healthcare system has a poor safety record when compared to other major industries. For example, at 250,000 per year, medical errors are the 3rd leading cause of death according to the CDC. [...]

By | 2019-03-11T14:23:46-04:00 March 11th, 2019|Hospital Medicine 2019, Innovations, Quality Improvement|Comments Off on COMBINING LEAN SIX-SIGMA QUALITY IMPROVEMENT METHODS WITH SAFETY BARRIER ANALYSIS TO DEVELOP INTERVENTIONS THAT REDUCE HOSPITAL-ACQUIRED VENOUS THROMBOEMBOLISM (HA-VTE)

HM2018 Abstract Number: 250

APPLICATION OF DATA ANALYTICS AND BOWTIE RISK METHODOLOGY TO REDUCE RATES OF HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM

Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a serious public health problem causing over 90,000 deaths each year. VTE rates at our institution have been high and costly, with insurer [...]

By | 2018-03-19T15:44:14-04:00 March 19th, 2018|Innovations, Quality Improvement, Uncategorized|Comments Off on APPLICATION OF DATA ANALYTICS AND BOWTIE RISK METHODOLOGY TO REDUCE RATES OF HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM

HM2018 Abstract Number: 144

ECONOMIC BENEFIT FOR ACUTE-CARE HOSPITALS THROUGH USING BETRIXABAN FOR EXTENDED-DURATION VTE PROPHYLAXIS OVER 35-42 DAYS

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and [...]

By | 2018-03-19T13:10:12-04:00 March 19th, 2018|Hospital Medicine 2018, Outcomes Research, Research|Comments Off on ECONOMIC BENEFIT FOR ACUTE-CARE HOSPITALS THROUGH USING BETRIXABAN FOR EXTENDED-DURATION VTE PROPHYLAXIS OVER 35-42 DAYS

HM2018 Abstract Number: 145

EXTENDED-DURATION VTE PROPHYLAXIS WITH BETRIXABAN SAVES COST COMPARED TO STANDARD-DURATION ENOXAPARIN ACROSS INPATIENT AND OUTPATIENT SETTINGS

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and [...]

By | 2018-03-19T13:09:33-04:00 March 19th, 2018|Hospital Medicine 2018, Outcomes Research, Research|Comments Off on EXTENDED-DURATION VTE PROPHYLAXIS WITH BETRIXABAN SAVES COST COMPARED TO STANDARD-DURATION ENOXAPARIN ACROSS INPATIENT AND OUTPATIENT SETTINGS

HM2018 Abstract Number: 287

ENGAGEMENT WITH A NOVEL PATIENT-FACING MOBILE HEALTH APPLICATION AMONG PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM

Background: Mobile health applications have the potential to support patients via improved engagement and self-management. While the use of this technology has been developed for patients with chronic diseases, there is limited evidence to guide [...]

By | 2018-03-19T13:02:14-04:00 March 19th, 2018|Hospital Medicine 2018, Research, Technology in Hospital Medicine|Comments Off on ENGAGEMENT WITH A NOVEL PATIENT-FACING MOBILE HEALTH APPLICATION AMONG PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM

HM2018 Abstract Number: 116

PERIPROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTS WITH VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW

Background: Vitamin K antagonists (VKA) remain widely used in the treatment of venous thromboembolism (VTE). During surgical interventions, the prevention of recurrent VTE must be weighed against the increased bleeding risk conferred by anticoagulation. There [...]

By | 2018-03-19T12:54:21-04:00 March 19th, 2018|Hospital Medicine 2018, Outcomes Research, Research|Comments Off on PERIPROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTS WITH VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW

HM2017 Abstract Number: 429

A CASE OF POST-OPERATIVE DEEP VEIN THROMBOSIS IN A HYPERCOAGULABLE PATIENT ON APIXABAN

Case Presentation: Hypercoagulable disorders pose an increased lifetime risk of developing venous thromboembolic events (VTE). It is established that patients with these disorders usually need lifelong anticoagulation once they have more than one thromboembolic event. [...]

By | 2017-04-25T17:28:16-04:00 April 20th, 2017|Adult, Clinical Vignette Abstracts|Comments Off on A CASE OF POST-OPERATIVE DEEP VEIN THROMBOSIS IN A HYPERCOAGULABLE PATIENT ON APIXABAN